---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-022613"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:15:46.008928+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path

## Summary
- No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.
- Raised $9.2M net from stock sales and converted $1.1M debt to equity during quarter.
- Licensed AI-ECG algorithms and IP from Icahn School of Medicine at Mount Sinai; Mount Sinai became largest shareholder.
- FDA pathway changed to 510(k) for MyoVista device; targeting FDA clearance around calendar year-end 2024.
- Peer-reviewed study showed MyoVista AI-ECG outperformed standard screening for heart disease in diabetic patients.

## SEC filing metadata
- accession: 0001213900-24-022613
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/0001213900-24-022613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/ea0201847-8k_hearttest.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-022613
- JSON: https://secwatch.observer/filing/0001213900-24-022613.json
- Plain text: https://secwatch.observer/filing/0001213900-24-022613.txt

## Key facts
- Earnings Releases
  HeartSciences Inc. reported third quarter fiscal 2024 ended January 31, 2024 results: revenue There were no significant revenues in the third quarter fiscal 2024..
  - Period: third quarter fiscal 2024 ended January 31, 2024
  - Revenue: There were no significant revenues in the third quarter fiscal 2024.
  - Result: reported results
  source text: HeartSciences Reports Third Quarter Fiscal 2024 Financial Results Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc . d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/0001213900-24-022613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.